期刊文献+

紫杉醇持续滴注联合方案二线治疗难治性晚期食管鳞癌 被引量:5

Continuous Intravenous Infusion Paclitaxel Based Combination Regimen as Second Line Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma
原文传递
导出
摘要 [目的]研究含紫杉醇(PTX)持续静脉滴注方案二线治疗晚期食管癌的疗效和毒性。[方法]26例晚期食管鳞癌患者应用含低剂量PTX持续静脉输注联合方案化疗:PTX20mg/m2,civ,16h,d1~3,d8~9;DDP3.75mg/m2,iv,d1~4,d8~11;5-Fu375mg/m2,civ,24h,d1~5,d8~12;叶酸60mg,po,d1~5,d8~12;21d为1个周期,至少应用2个周期。[结果]23例完成2个周期治疗者可评价疗效,CR1例,PR9例,SD10例,PD3例,有效率为43.5%,中位疾病进展时间(TTP)5.1个月。主要毒副反应为骨髓抑制和脱发,其他毒副反应较轻。[结论]低剂量PTX持续静脉输注联合方案治疗晚期食管鳞癌安全有效。 [Purpose] To investigate the response and toxicity of continuous intravenous infusion paclitaxel based combination regimen as second line chemotherapy for advanced esophageal squamous cell carcinoma(ESCC).[Methods] Twenty-six with ESCC pathologically proved received continuous intravenous infusion paclitaxel(PTX) based combination regimen.The regimen schedule was:PTX 20mg/m2,civ,16h,d1-3,d8-9;DDP 3.75mg/m2,iv,d1-4,d8-11,5-Fu 375mg/m2,civ,24h,d1-5,d8-12;folic acid 60mg,po,d1-5,d8-12.Twenty-one days as a cycle,and each patient was treated at least two cycles.[Results] Response was evaluable in 23 cases with≥2 cycles,1 case in CR,9 cases in PR,10 cases in SD and 3 cases in PD,the overall response rate was 43.5%.The median TTP was 5.1 months.The main toxicities were myelosuppression and alopecia,and other toxicities were mild.[Conclusion] Continuous intravenous infusion paclitaxel based combination regimen for advanced ESCC is effective and tolerable.
出处 《肿瘤学杂志》 CAS 2010年第11期889-891,共3页 Journal of Chinese Oncology
基金 南京医科大学科技发展基金重点项目(2010Njmuz48)
关键词 食管肿瘤 紫杉醇 持续静脉滴注 顺铂 氟尿嘧啶 药物疗法 esophageal neoplasm paclitaxel continuous intravenous infusion cisplatin fluorouracil drug therapy
  • 相关文献

参考文献10

二级参考文献105

  • 1黄镜,蔡锐刚,孟平均,张明娟,崔成旭,杨林,储大同,孙燕,王金万.紫杉醇联合顺铂治疗晚期食管鳞癌[J].中华肿瘤杂志,2004,26(12):753-755. 被引量:96
  • 2Shih-Ching Chang,Jen-Kou Lin,Tzu-Chen Lin,Wen-Yih Liang.Loss of heterozygosity: An independent prognostic factor of colorectal cancer[J].World Journal of Gastroenterology,2005,11(6):778-784. 被引量:2
  • 3吴成利,秦叔逵.食管癌的化疗新进展[J].医师进修杂志(外科版),2005,28(4):6-8. 被引量:20
  • 4黄伟钊,傅剑华,胡祎,张旭,杨弘.食管癌术后辅助化疗价值的Meta分析[J].癌症,2006,25(10):1303-1306. 被引量:25
  • 5李醒亚,周芳,任中海,赵永福,路平,王俊生,郑安平,库建伟.洛铂联合5-氟尿嘧啶与亚叶酸钙治疗晚期食管癌的Ⅱ期临床研究[J].中华肿瘤防治杂志,2007,14(1):64-66. 被引量:18
  • 6Misset JT, Gamelin E, Compone M, et al. Phase Ⅰ and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors [ J ] . Ann Oncol, 2004, 15(7): 1123- 1129.
  • 7Mackay H J, McInnes A, Paul J, et al. A phase Ⅱ study of epirubicin, cisplatin and rahitrexed combination chemotherapy(ECT) in patients with advanced oesophageal and gastric adenocarcinoma [ J ] . Ann Oncol, 2001, 12(10): 1407-1410.
  • 8Safran H, Suntharalingam M, Dipetrillo T, et al. Cetuximab with concurrent chemoradiation for esophagogastric cancer: Assessment of toxicity[J].Int J Radiat Oncol Biol Phys, 2008, 70(2): 391-395.
  • 9Safran H, DiPetrillo T, Akerman P, et al. Phase Ⅰ/Ⅱ study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma [ J ] . Int J Radiat Oncol Biol Phys, 2007, 67(2): 405-409.
  • 10Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, et al. Predictive factors for outcome in a phase Ⅱ study of gefitinib in second-line treatment of advanced esophageal cancer patients [ J ] . J Clin Oncol, 2006, 24(34): 5465.

共引文献45

同被引文献47

  • 1刘伟巍,李苏宜.肿瘤患者进食能力内科临床技术路线[J].肿瘤学杂志,2023,29(4):270-275.
  • 2马怀幸,李苏宜.癌性恶液质临床建议路径[J].肿瘤学杂志,2022,28(12):1007-1013. 被引量:3
  • 3李苏宜.营养不良肿瘤患者抗肿瘤药物治疗临床建议路径[J].肿瘤学杂志,2022,28(12):988-990. 被引量:7
  • 4Zhao ZS,Wang YY,Ye ZY,et al. Prognostic value of tumor- related molecular expression in gastric carcinoma[J]. Pathol Oncol Res, 2009,15 (4) : 589-596.
  • 5West HL,Crowley JJ,Vance RB, et al. Advanced bronchio- loalveolar carcinoma:a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714):a Southwest Oncology Group study [J]. Ann Oncol, 2005,16(7) : 1076-1080.
  • 6Lee KW, Im SA, Yun T, et al. Phase ]I Trial of low-dose paclitaxel and eisplatin in patients with advanced gastric cancer[J]. Jpn J Clin Oneol, 2005,35 (12) : 720-726.
  • 7Kim JY,Do YR,Park KU,et al. Multicenter phase II trial of S-l,paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer[J]. Cancer Chemo ther Pharmacol, 2011,67(3) : 527-532.
  • 8Okita A, Miyade Y, Okano K. Effective management of an advanced gastric cancer patient by TS-1 combined chemo- therapy using nasojejunal tube and successful transfer to home care after percutaneous transesophageal gastro-tubing (PTEG) : a case report[J]. Acta Med Okayama, 2010,64 ( 1 ) : 67 -70.
  • 9Ueda Y, Yamagishi H, Ichikawa D, et al. Multicenter phase study of weekly paclitaxel plus S-1 combination chemo therapy in patients with advanced gastric cancer[J]. Gastric Cancer, 2010,13(3) : 149-154.
  • 10Xu X, Wang L, Xu HQ, et al. Clinical comparison between paclitaxel liposome (Lipusu) and paclitaxel for treatment of patients with metastatic gastric cancer[J]. Asian Pac J Cancer Prev, 2013,14(4) : 2591 2594.

引证文献5

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部